首页>
外国专利>
FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR TREATING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE
FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR TREATING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE
展开▼
机译:粪乳铁蛋白作为生物标记物,用于确定患有严重艰难梭菌疾病的患者的疾病严重性和治疗感染
展开▼
页面导航
摘要
著录项
相似文献
摘要
Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.
展开▼